|
1
|
Health Professional Version, .
Neuroblastoma Treatment (PDQ®)-Health Professional
VersionNational Cancer Institute; Bethesda, MD: 2014, https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq
|
|
2
|
Gatta G, Botta L, Rossi S, Aareleid T,
Bielska-Lasota M, Clavel J, Dimitrova N, Jakab Z, Kaatsch P, Lacour
B, et al: Childhood cancer survival in Europe 1999–2007: Results of
EUROCARE-5-a population-based study. Lancet Oncol. 15:35–47. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brodeur GM and Bagatell R: Mechanisms of
neuroblastoma regression. Nat Rev Clin Oncol. 11:704–713. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li P, Gao Y, Ji Z, Zhang X, Xu Q, Li G,
Guo Z, Zheng B and Guo X: Role of urokinase plasminogen activator
and its receptor in metastasis and invasion of neuroblastoma. J
Pediatr Surg. 39:1512–1519. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matthay KK, Maris JM, Schleiermacher G,
Nakagawara A, Mackall CL, Diller L and Weiss WA: Neuroblastoma. Nat
Rev Dis Primers. 2:160782016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mazar J, Li Y, Rosado A, Phelan P,
Kedarinath K, Parks GD, Alexander KA and Westmoreland TJ: Zika
virus as an oncolytic treatment of human neuroblastoma cells
requires CD24. PLoS One. 13:e02003582018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smith MA, Altekruse SF, Adamson PC, Reaman
GH and Seibel NL: Declining childhood and adolescent cancer
mortality. Cancer. 120:2497–2506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwon C, Han Z, Olson EN and Srivastava D:
MicroRNA1 influences cardiac differentiation in Drosophila and
regulates Notch signaling. Proc Natl Acad Sci USA. 102:18986–18991.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ro S, Park C, Young D, Sanders KM and Yan
W: Tissue-dependent paired expression of miRNAs. Nucleic Acids Res.
35:5944–5953. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mallory AC and Vaucheret H: MicroRNAs:
Something important between the genes. Curr Opin Plant Biol.
7:120–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambros V: microRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2001. View Article : Google Scholar
|
|
16
|
Chen JY, Yao DS, He CJ, et al:
Differential expression of microRNA in cervical squamous cell
carcinoma. J Pract Med. 30:83–87. 2014.
|
|
17
|
Sathipati SY and Ho SY: Identifying the
miRNA signature associated with survival time in patients with lung
adenocarcinoma using miRNA expression profiles. Sci Rep.
7:2017.
|
|
18
|
Chen Q, Zhou Y, Richards AM and Wang P:
Up-regulation of miRNA-221 inhibits hypoxia/reoxygenation-induced
autophagy through the DDIT4/mTORC1 and Tp53inp1/p62 pathways.
Biochem Biophys Res Commun. 474:168–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu CG, Yang MF, Fan JX and Wang W: MiR-30a
and miR-205 are downregulated in hypoxia and modulate
radiosensitivity of prostate cancer cells by inhibiting autophagy
via TP53INP1. Eur Rev Med Pharmacol Sci. 20:1501–1508.
2016.PubMed/NCBI
|
|
20
|
Wang W, Liu J and Wu Q: MiR-205 suppresses
autophagy and enhances radiosensitivity of prostate cancer cells by
targeting TP53INP1. Eur Rev Med Pharmacol Sci. 20:92–100.
2016.PubMed/NCBI
|
|
21
|
Seillier M, Peuget S, Gayet O, Gauthier C,
NGuessan P, Monte M, Carrier A, Iovanna JL and Dusetti NJ:
TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family
proteins through the LC3-interacting region (LIR) and promotes
autophagy-dependent cell death. Cell Death Differ. 19:1525–1535.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saadi H, Seillier M and Carrier A: The
stress protein TP53INP1 plays a tumor suppressive role by
regulating metabolic homeostasis. Biochimie. 118:44–50. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue X, Wang X, Zhao Y, Hu R and Qin L:
Exosomal miR-93 promotes proliferation and invasion in
hepatocellular carcinoma by directly inhibiting
TIMP2/TP53INP1/CDKN1A. Biochem Biophys Res Commun. 502:515–521.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Sun H, Zhang D, Fan D, Zhang Y,
Dong X, Liu S, Yang Z, Ni C, Li Y, et al: TP53INP1 inhibits
hypoxia-induced vasculogenic mimicry formation via the ROS/snail
signalling axis in breast cancer. J Cell Mol Med. 22:3475–3488.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cai Q, Zeng S, Dai X, Wu J and Ma W:
miR-504 promotes tumour growth and metastasis in human osteosarcoma
by targeting TP53INP1. Oncol Rep. 38:2993–3000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X
and Qiu G: MicroRNA-10b promotes nucleus pulposus cell
proliferation through RhoC-Akt pathway by targeting HOXD10 in
intervetebral disc degeneration. PLoS One. 8:e830802013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Yu X, Shen J, Wu WK and Chan MT:
MicroRNA expression and its clinical implications in Ewings
sarcoma. Cell Prolif. 48:1–6. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu X and Li Z: MicroRNAs regulate vascular
smooth muscle cell functions in atherosclerosis (review). Int J Mol
Med. 34:923–933. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li M, Yu M, Liu C, Zhu H, He X, Peng S and
Hua J: miR-34c works downstream of p53 leading to dairy goat male
germline stem-cell (mGSCs) apoptosis. Cell Prolif. 46:223–231.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie
T, Zhang J, Peng C, Lin Y and Chen J: MicroRNA-25 regulates
chemoresistance-associat-ed autophagy in breast cancer cells, a
process modulated by the natural autophagy inducer
isoliquiritigenin. Oncotarget. 5:7013–7026. 2014.PubMed/NCBI
|
|
32
|
Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei
Y, Li Y, Yang Q, Liu J, Wei JJ, et al: miR-145 inhibits tumor
growth and metastasis by targeting metadherin in high-grade serous
ovarian carcinoma. Oncotarget. 5:10816–10829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y,
Liu C, Song W, Wang F, Zhang J, et al: DNA methylation
downregulated mir-10b acts as a tumor suppressor in gastric cancer.
Gastric Cancer. 18:43–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J
and Feng F: By downregulating TIAM1 expression, microRNA-329
suppresses gastric cancer invasion and growth. Oncotarget.
6:17559–17569. 2015.PubMed/NCBI
|
|
35
|
Li Z, Yu X, Shen J and Jiang Y: MicroRNA
dysregulation in uveal melanoma: A new player enters the game.
Oncotarget. 6:4562–4568. 2015.PubMed/NCBI
|
|
36
|
Li J, You T and Jing J: MiR-125b inhibits
cell biological progression of Ewings sarcoma by suppressing the
PI3K/Akt signalling pathway. Cell Prolif. 47:152–160. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schirmer U, Doberstein K, Rupp AK, Bretz
NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E,
Zeillinger R, et al: Role of miR-34a as a suppressor of L1CAM in
endometrial carcinoma. Oncotarget. 5:462–472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang PH, Motoo Y, Garcia S, Iovanna JL,
Pébusque MJ and Sawabu N: Down-expression of tumor protein
p53-induced nuclear protein 1 in human gastric cancer. World J
Gastroenterol. 12:691–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tomasini R, Samir AA, Carrier A, Isnardon
D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL and
Dusetti NJ: TP53INP1s and homeodomain-interacting protein kinase-2
(HIPK2) are partners in regulating p53 activity. J Biol Chem.
278:37722–37729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liao D, Li T, Ye C, Zeng L, Li H, Pu X,
Ding C, He Z and Huang GL: miR-221 inhibits autophagy and targets
TP53INP1 in colorectal cancer cells. Exp Ther Med. 15:1712–1717.
2018.PubMed/NCBI
|
|
41
|
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS,
Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b Promotes
CD133(+) liver tumor-initiating cell growth and self-renewal via
tumor protein 53-induced nuclear protein 1. Cell Stem Cell.
7:694–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang F, Liu T, He Y, Yan Q, Chen X, Wang
H and Wan X: MiR-125b promotes proliferation and migration of type
II endometrial carcinoma cells through targeting TP53INP1 tumor
suppressor in vitro and in vivo. BMC Cancer. 11:4252011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seux M, Peuget S, Montero MP, Siret C,
Rigot V, Clerc P, Gigoux V, Pellegrino E, Pouyet L, NGuessan P, et
al: TP53INP1 decreases pancreatic cancer cell migration by
regulating SPARC expression. Oncogene. 30:3049–3061. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Giusiano S, Baylot V, Andrieu C, Fazli L,
Gleave M, Iovanna JL, Taranger-Charpin C, Garcia S and Rocchi P:
TP53INP1 as new therapeutic target in castration-resistant prostate
cancer. Prostate. 72:1286–1294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gironella M, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155, and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chaluvally-Raghavan P, Zhang F, Pradeep S,
Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, et
al: Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of
TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell.
26:863–879. 2014. View Article : Google Scholar : PubMed/NCBI
|
